Amid efforts on several fronts to improve the affordability of its GLP-1 medications for diabetes and obesity, Novo Nordisk is taking a new approach by aiming straight for semaglutide’s list price.

Just three months after further scaling back its support for the struggling hemophilia A gene therapy Roctavian, the company is walking away altogether by pulling the treatment from the market.

Looking to gain an edge as its broader obesity ambitions take shape, Pfizer has picked up the rights to a recently approved GLP-1 in China, unlocking an immediate commercial opportunity in type 2 diabetes, with the potential for a weight loss nod not far behind.

Havas will lead Indivior’s integrated strategy, creative, media and digital efforts across healthcare professional and direct-to-consumer audiences.

AstraZeneca is giving Pascal Soriot a pay raise as the longtime CEO weathered a year of “significant geopolitical uncertainty” to advance the British pharma toward an ambitious 2030 goal.

The family of a Baltimore woman whose cells were extracted for medical research without her consent 75 years ago has settled a lawsuit with Novartis, with terms of the agreement confidential. Lawsuits the estate has filed against Ultragenyx and Viatris remain active.